CL2019003153A1 - Métodos para el tratamiento del síndrome de alport. - Google Patents
Métodos para el tratamiento del síndrome de alport.Info
- Publication number
- CL2019003153A1 CL2019003153A1 CL2019003153A CL2019003153A CL2019003153A1 CL 2019003153 A1 CL2019003153 A1 CL 2019003153A1 CL 2019003153 A CL2019003153 A CL 2019003153A CL 2019003153 A CL2019003153 A CL 2019003153A CL 2019003153 A1 CL2019003153 A1 CL 2019003153A1
- Authority
- CL
- Chile
- Prior art keywords
- alport syndrome
- modified oligonucleotide
- mir
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501699P | 2017-05-04 | 2017-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003153A1 true CL2019003153A1 (es) | 2020-03-27 |
Family
ID=62223298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003153A CL2019003153A1 (es) | 2017-05-04 | 2019-11-04 | Métodos para el tratamiento del síndrome de alport. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210100828A1 (https=) |
| EP (1) | EP3618838A1 (https=) |
| JP (2) | JP2020518633A (https=) |
| KR (1) | KR20190141770A (https=) |
| CN (2) | CN110740737A (https=) |
| AU (1) | AU2018261792A1 (https=) |
| BR (1) | BR112019022824A2 (https=) |
| CA (1) | CA3062316A1 (https=) |
| CL (1) | CL2019003153A1 (https=) |
| MA (1) | MA50749A (https=) |
| MX (1) | MX2019013158A (https=) |
| SG (1) | SG11201910099WA (https=) |
| WO (1) | WO2018204788A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076452A1 (en) * | 2020-10-05 | 2022-04-14 | Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital | Combination therapy for alport renal disease |
| CN120731923B (zh) * | 2025-09-05 | 2025-11-04 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498315B2 (en) * | 2004-06-01 | 2009-03-03 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| NZ601660A (en) * | 2008-08-25 | 2014-05-30 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| US20150031750A1 (en) * | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| PE20142404A1 (es) * | 2012-04-25 | 2015-02-02 | Regulus Therapeutics Inc | Compuestos de microarn y metodos de modulacion de la actividad de mir-21 |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
-
2018
- 2018-05-04 US US16/607,971 patent/US20210100828A1/en not_active Abandoned
- 2018-05-04 MA MA050749A patent/MA50749A/fr unknown
- 2018-05-04 KR KR1020197035568A patent/KR20190141770A/ko not_active Ceased
- 2018-05-04 WO PCT/US2018/031094 patent/WO2018204788A1/en not_active Ceased
- 2018-05-04 SG SG11201910099W patent/SG11201910099WA/en unknown
- 2018-05-04 CA CA3062316A patent/CA3062316A1/en active Pending
- 2018-05-04 AU AU2018261792A patent/AU2018261792A1/en not_active Abandoned
- 2018-05-04 CN CN201880037914.1A patent/CN110740737A/zh active Pending
- 2018-05-04 JP JP2019560355A patent/JP2020518633A/ja active Pending
- 2018-05-04 MX MX2019013158A patent/MX2019013158A/es unknown
- 2018-05-04 BR BR112019022824A patent/BR112019022824A2/pt not_active IP Right Cessation
- 2018-05-04 EP EP18726668.9A patent/EP3618838A1/en not_active Withdrawn
- 2018-05-04 CN CN202310591916.8A patent/CN116585344A/zh active Pending
-
2019
- 2019-11-04 CL CL2019003153A patent/CL2019003153A1/es unknown
-
2021
- 2021-09-14 US US17/474,264 patent/US20220133769A1/en not_active Abandoned
-
2023
- 2023-02-17 JP JP2023023048A patent/JP2023075111A/ja active Pending
- 2023-08-09 US US18/446,743 patent/US20240115598A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190141770A (ko) | 2019-12-24 |
| US20220133769A1 (en) | 2022-05-05 |
| JP2023075111A (ja) | 2023-05-30 |
| AU2018261792A1 (en) | 2020-01-02 |
| CN116585344A (zh) | 2023-08-15 |
| RU2019139261A3 (https=) | 2021-09-06 |
| EP3618838A1 (en) | 2020-03-11 |
| WO2018204788A1 (en) | 2018-11-08 |
| BR112019022824A2 (pt) | 2020-06-09 |
| JP2020518633A (ja) | 2020-06-25 |
| SG11201910099WA (en) | 2019-11-28 |
| US20210100828A1 (en) | 2021-04-08 |
| CA3062316A1 (en) | 2018-11-08 |
| MA50749A (fr) | 2020-03-11 |
| US20240115598A1 (en) | 2024-04-11 |
| MX2019013158A (es) | 2020-02-07 |
| CN110740737A (zh) | 2020-01-31 |
| RU2019139261A (ru) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35069A (es) | Métodos para el tratamiento del síndrome de alport | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| MX388743B (es) | Conjugados oligonucleótido-péptido. | |
| IL263670B (en) | Assemblies and methods for infusion pump system delivery kits | |
| MX2017011638A (es) | Dispositivos magnéticos de anastomosis con fuerza magnética variada a una distancia. | |
| MX2018007307A (es) | Conjugados de peptidos y oligonucleotidos. | |
| CL2019003153A1 (es) | Métodos para el tratamiento del síndrome de alport. | |
| SE1651369A1 (sv) | Pef chamber | |
| AR128192A2 (es) | Métodos para el tratamiento del síndrome de alport | |
| AR119688A2 (es) | Métodos para el tratamiento del síndrome de alport | |
| EA201691964A1 (ru) | Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии | |
| EA201891587A1 (ru) | Лиофилизированная перентеральная композиция тигециклина и способ ее приготовления | |
| NI201600061A (es) | Formulaciones de inyección con base en aceite de sésamo | |
| Cho | Pseudo-Einstein manifolds | |
| EP3373856A4 (en) | MOBILE EYE PROTECTION AND ASSOCIATED SYSTEMS AND METHOD THEREFOR | |
| EA201791442A1 (ru) | Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров | |
| EA202191503A1 (ru) | Комбинированные терапии для мдс высокого и очень высокого риска | |
| 高妙男 | Report on CE Translation of Gsm Enterprise Website | |
| TH64396B (th) | เข็มเจาะเพื่อให้สารน้ำทางเส้นเลือดดำแบบปลอดภัยและสามารถใช้แล้วทิ้งได้ | |
| 姚卓丹 | Reflective Nationalism: A Study on Post-National Identity in the Untouchable | |
| 李煜 | An Analysis of Apologies in American Sitcom The BIG Bang Theory from The Perspective of Politeness Principle | |
| 杨甜甜 | A Study on Ec Auto News Trans-editing Based on Text Typology Theory | |
| მარიამ გაბისონია et al. | ინტერვიუ | |
| 章思思 | On the Application of Functional Equivalence Theory in the Translation of Japanese Legal Documents | |
| PL122770U1 (pl) | Przedłużacz do pomp |